Detection of metastases in sentinel lymph nodes of breast cancer patients by multiple‐marker RT‐PCR

This study was undertaken to assess a multiple‐marker RT‐PCR and Southern blot assay for detection of metastases in frozen sections of sentinel lymph nodes from breast cancer patients. Sentinel lymphadenectomy was performed in 41 AJCC (American Joint Committee on Cancer) stage I‐IIIA breast cancer patients and 57 sentinel nodes (SNs) were excised. The SN, which is the first node in the lymphatic basin to receive metastases from the primary tumor, was identified using isosulfan blue dye. Hematoxylin and eosin (H&E), immuno‐histochemistry (IHC) and RT‐PCR were performed on adjacent sections of the SN. Six consecutive 12‐μm frozen sections of each SN were obtained for the RT‐PCR assay to determine expression of mRNA tumor markers C‐Met, β1 → 4GalNAc‐T and P97. Metastatic breast cancer was detected by H&E in 10 of 57 (18%) SNs and by IHC in an additional 7 (12%). Only 1 of 17 (6%) SNs with metastases did not express any of the 3 tumor mRNA markers. C‐Met, β1 → 4GalNAc‐T and P97 tumor mRNA markers were expressed in 31 (78%), 21 (53%) and 25 (63%) of 40 SNs without metastases, respectively. At least 2 mRNA tumor markers were expressed in 25/40 (63%) histo‐pathologically tumor‐free SNs, whereas all 3 mRNA tumor markers were expressed in 17/40 (43%) SNs. Expression of all 3 mRNA tumor markers in a SN was significantly higher in patients with a family history of breast cancer (p= 0.05), prior history of breast cancer (p< 0.05), infiltrating lobular carcinoma (p = 0.06), estrogen receptor‐negative (p= 0.04) tumor or a higher Bloom Richardson score (p= 0.04). The multiple‐marker RT‐PCR and Southern blot assay improves the detection of occult metastases in the SN when compared to conventional H&E and IHC analysis. Expression of all 3 tumor mRNA markers in the SN correlated with poor prognostic clinico‐pathologic factors compared to expression of 0 to 2 markers. Int. J. Cancer (Pred. Oncol.) 79:645–651, 1998. © 1998 Wiley‐Liss, Inc.

[1]  S. Hellman,et al.  Karnofsky Memorial Lecture. Natural history of small breast cancers. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Giuliano,et al.  Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  K. Furukawa,et al.  Genetic and enzymatic basis for the differential expression of GM2 and GD2 gangliosides in human cancer cell lines. , 1993, Cancer research.

[4]  J. Ryś,et al.  Flow cytometric DNA-analysis of cells obtained with fine needle aspiration biopsy of the breast. , 1996, General & diagnostic pathology.

[5]  D. Morton,et al.  Assessment of messenger RNA of beta 1-->4-N-acetylgalactosaminyl-transferase as a molecular marker for metastatic melanoma. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  A. Giuliano,et al.  Improved Axillary Staging of Breast Cancer with Sentinel Lymphadenectomy , 1995, Annals of surgery.

[7]  P. Saigo,et al.  Axillary Micro- and Macrometastases in Breast Cancer: Prognostic Significance of Tumor Size , 1981, Annals of surgery.

[8]  Shinzaburo Noguchi,et al.  The detection of breast carcinoma micrometastases in axillary lymph nodes by means of reverse transcriptase‐polymerase chain reaction , 1994, Cancer.

[9]  K. Mimori,et al.  Detection of cancer micrometastases in lymph nodes by reverse transcriptase-polymerase chain reaction. , 1995, Cancer research.

[10]  R. Turner,et al.  Detection of metastatic breast cancer by β‐hCG polymerase chain reaction , 1996 .

[11]  Internationalludwigbreastcanc.  Prognostic importance of occult axillary lymph node micrometastases from breast cancers , 1990 .

[12]  B. Nordlinger,et al.  Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  G. V. Vande Woude,et al.  The met proto-oncogene receptor and lumen formation. , 1992, Science.

[14]  A Böcking,et al.  Interobserver reproducibility of immunocytochemical estrogen- and progesterone receptor status assessment in breast cancer. , 1996, Anticancer research.

[15]  C. Kainz,et al.  Infiltrating ductal carcinoma of the breast: extensive intraductal component has no impact on lymph node involvement and survival. , 1995, Anticancer research.

[16]  Rika Deraemaecker,et al.  Expression of MAGE genes in primary and metastatic cutaneous melanoma , 1995, International journal of cancer.

[17]  S. Noguchi,et al.  Detection of breast cancer micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction. Comparison between MUC1 mRNA and keratin 19 mRNA amplification. , 1996, The American journal of pathology.

[18]  S. Ethier,et al.  Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  W. Dreyer,et al.  Primary structure of the human melanoma-associated antigen p97 (melanotransferrin) deduced from the mRNA sequence. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[20]  N. Hamajima,et al.  Impact of Family History on the Risk of Breast Cancer among the Japanese , 1997, Japanese journal of cancer research : Gann.

[21]  A. Purushotham,et al.  Hepatocyte growth factor/scatter factor expression and c-met in primary breast cancer. , 1996, Surgical oncology.

[22]  R. Kramer,et al.  Expression of the C‐Met/HGF receptor in human breast carcinoma: Correlation with tumor progression , 1997, International journal of cancer.

[23]  E. Gherardi,et al.  Hepatocyte growth factor--scatter factor: mitogen, motogen, and met. , 1991, Cancer cells.

[24]  S Hellman,et al.  Natural history of node-negative breast cancer: a study of 826 patients with long-term follow-up. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  G. Schwarzmann,et al.  Both GA2, GM2, and GD2 synthases and GM1b, GD1a, and GT1b synthases are single enzymes in Golgi vesicles from rat liver. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[26]  M. Nakahara,et al.  Independent prognostic factors in breast cancer patients. , 1998, American journal of surgery.

[27]  H. Rockette,et al.  Detection and significance of occult axillary node metastases in patients with invasive breast cancer , 1978, Cancer.

[28]  S. Shousha,et al.  Detection of breast cancer micrometastases in axillary lymph nodes by using polymerase chain reaction. , 1994, Cancer research.

[29]  A E Giuliano,et al.  Sentinel lymphadenectomy in breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  D. Hoon,et al.  Ganglioside GM2 expression on human melanoma cells correlates with sensitivity to lymphokine‐activated killer cells , 1989, International journal of cancer.

[31]  D L Morton,et al.  Technical details of intraoperative lymphatic mapping for early stage melanoma. , 1992, Archives of surgery.

[32]  D. Slamon,et al.  HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  P. Comoglio,et al.  Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression. , 1993, British Journal of Cancer.

[34]  P Zola,et al.  Overexpression of the MET/HGF receptor in ovarian cancer , 1994, International journal of cancer.

[35]  B. Asselain,et al.  S-phase fractions of breast cancer predict overall and post-relapse survival. , 1997, European journal of cancer.

[36]  J. Yodoi,et al.  Expression cloning of beta 1,4 N-acetylgalactosaminyltransferase cDNAs that determine the expression of GM2 and GD2 gangliosides. , 1992, The Journal of biological chemistry.

[37]  S. Hakomori.  Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. , 1996, Cancer research.

[38]  J. Rowley,et al.  The human met oncogene is related to the tyrosine kinase oncogenes , 1985, Nature.

[39]  D. Garrison,et al.  Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  P. Stalmeier,et al.  A review on family history of breast cancer: screening and counseling proposals for women with familial (non-hereditary) breast cancer. , 1997, Patient education and counseling.

[41]  U. Chetty,et al.  Prospective evaluation of prognostic factors in operable breast cancer. , 1996, British Journal of Cancer.

[42]  J. Brown,et al.  Structural characterization of human melanoma-associated antigen p97 with monoclonal antibodies. , 1981, Journal of immunology.

[43]  T. Nakamura,et al.  Role of hepatocyte growth factor in breast cancer: a novel mitogenic factor secreted by adipocytes. , 1994, DNA and cell biology.

[44]  B. Elliott,et al.  Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma. , 1996, The American journal of pathology.

[45]  L. D. Leffall.  Presidential address: Surgical oncology‐expectations for the future , 1980, Cancer.

[46]  G. Tuccari,et al.  Immunocytochemical Demonstration Of Melanotransferrin (P97) In Thyroid Tumors Of Follicular Cell Origin , 1994, Pathology.

[47]  B. Asselain,et al.  Metachronous contralateral breast cancer as first event of relapse. , 1996, International journal of radiation oncology, biology, physics.

[48]  D. Morton,et al.  Aberrant expression of gangliosides in human renal cell carcinomas. , 1993, The Journal of urology.

[49]  D. Garrison,et al.  Melanoma-associated antigens as messenger RNA detection markers for melanoma. , 1997, Cancer research.

[50]  A. Leathem,et al.  Expression of alpha-GalNAc glycoproteins by breast cancers. , 1995, British Journal of Cancer.